A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention.
Kwon YD, Asokan M, Gorman J, Zhang B, Liu Q, Louder MK, Lin BC, McKee K, Pegu A, Verardi R, Yang ES, Program VP, Carlton K, Doria-Rose NA, Lusso P, Mascola JR, Kwong PD.
Kwon YD, et al. Among authors: louder mk.
MAbs. 2021 Jan-Dec;13(1):1946918. doi: 10.1080/19420862.2021.1946918.
MAbs. 2021.
PMID: 34328065
Free PMC article.
Review.